Number of the records: 1
FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells
- 1.0540544 - BC 2021 RIV CH eng J - Journal Article
Štefánik, M. - Valdés, James J. - Ezebuo, F.C. - Haviernik, J. - Uzochukwu, I.C. - Fojtiková, M. - Salát, J. - Eyer, Luděk - Růžek, Daniel
FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells.
Microorganisms. Roč. 8, č. 4 (2020), č. článku 599. ISSN 2076-2607. E-ISSN 2076-2607
R&D Projects: GA MZd(CZ) NV16-34238A
Institutional support: RVO:60077344
Keywords : nucleoside inhibitors * virus * protein * screen * pele * fda * flavivirus * Zika virus * tick-borne encephalitis virus * West Nile virus * antiviral
OECD category: Microbiology
Impact factor: 4.128, year: 2020
Method of publishing: Open access
https://www.mdpi.com/2076-2607/8/4/599
Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested, i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.
Permanent Link: http://hdl.handle.net/11104/0318171
Number of the records: 1